Skip to main content
Top
Published in: Head & Neck Oncology 1/2010

Open Access 01-12-2010 | Research

Malignant head and neck paragangliomas: Is there an optimal treatment strategy?

Authors: Daniel J Moskovic, Joseph R Smolarz, Douglas Stanley, Camilo Jimenez, Michelle D Williams, Ehab Y Hanna, Michael E Kupferman

Published in: Head & Neck Oncology | Issue 1/2010

Login to get access

Abstract

Background

Little is known about management and prognosis for malignant head & neck paragangliomas. We reviewed records of these patients to determine optimal treatment strategies.

Methods

We reviewed 113 cases of head & neck paragangliomas treated at our institution from 1970 to 2005. Nineteen patients were included in the study. All had primary surgical treatment at another institution. Metastatic disease was treated with radiation, chemotherapy, or both. Survival and complications were evaluated. P values were determined by Fischer's exact test.

Results

All patients treated with chemotherapy and radiation age ≥ 40 years had disease progression. Of the patients < 40, two had stable disease; one had regression of disease with treatment. Patients without disease progression had better prognosis and were alive at last follow-up.

Conclusions

Clinical benefit was derived from aggressive treatment. However, careful consideration of the risks of observation versus intensive therapy should be undertaken when managing these patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Klein RD, Jin L, Rumilla K, Young WF, Lloyd RV: Germline SDHB mutations are common in patients with apparently sporadic sympathetic paragangliomas. Diagn Mol Pathol. 2008, 17: 94-100. 10.1097/PDM.0b013e318150d67c.CrossRefPubMed Klein RD, Jin L, Rumilla K, Young WF, Lloyd RV: Germline SDHB mutations are common in patients with apparently sporadic sympathetic paragangliomas. Diagn Mol Pathol. 2008, 17: 94-100. 10.1097/PDM.0b013e318150d67c.CrossRefPubMed
2.
go back to reference Romanski R: Chemodectoma (non-chromaffinic paraganglioma) of the carotid body with distant metastases; with illustrative case. Am J Pathol. 1954, 30: 1-13.PubMedCentralPubMed Romanski R: Chemodectoma (non-chromaffinic paraganglioma) of the carotid body with distant metastases; with illustrative case. Am J Pathol. 1954, 30: 1-13.PubMedCentralPubMed
3.
go back to reference Branham GH, Gnepp DR, O'McMenomey S, Friedman WH: Malignant paraganglioma--a case report and literature review. Otolaryngol Head Neck Surg. 1989, 101: 99-103.PubMed Branham GH, Gnepp DR, O'McMenomey S, Friedman WH: Malignant paraganglioma--a case report and literature review. Otolaryngol Head Neck Surg. 1989, 101: 99-103.PubMed
4.
go back to reference Lee JH, Barich F, Karnell LH, et al: National Cancer Data Base report on malignant paragangliomas of the head and neck. Cancer. 2002, 94: 730-737. 10.1002/cncr.10252.CrossRefPubMed Lee JH, Barich F, Karnell LH, et al: National Cancer Data Base report on malignant paragangliomas of the head and neck. Cancer. 2002, 94: 730-737. 10.1002/cncr.10252.CrossRefPubMed
5.
go back to reference Kupferman ME, Hanna EY: Paragangliomas of the head and neck. Curr Oncol Rep. 2008, 10: 156-161. 10.1007/s11912-008-0024-9.CrossRefPubMed Kupferman ME, Hanna EY: Paragangliomas of the head and neck. Curr Oncol Rep. 2008, 10: 156-161. 10.1007/s11912-008-0024-9.CrossRefPubMed
6.
go back to reference Manolidis S, Shohet JA, Jackson CG, Glasscock ME: Malignant glomus tumors. Laryngoscope. 1999, 109: 30-34. 10.1097/00005537-199901000-00007.CrossRefPubMed Manolidis S, Shohet JA, Jackson CG, Glasscock ME: Malignant glomus tumors. Laryngoscope. 1999, 109: 30-34. 10.1097/00005537-199901000-00007.CrossRefPubMed
7.
go back to reference Harrington SW, Clagett OT, Dockerty MB: Tumors of the carotid body: Clinical and pathologic considerations of twenty tumors affecting nineteen patients (one bilateral). Ann Surg. 1941, 114: 820-833. 10.1097/00000658-194111000-00003.PubMedCentralCrossRefPubMed Harrington SW, Clagett OT, Dockerty MB: Tumors of the carotid body: Clinical and pathologic considerations of twenty tumors affecting nineteen patients (one bilateral). Ann Surg. 1941, 114: 820-833. 10.1097/00000658-194111000-00003.PubMedCentralCrossRefPubMed
8.
go back to reference Druck NS, Spector GJ, Ciralsky RH, Ogura JH: Malignant Glomus vagale: report of a case and review of the literature. Arch Otolaryngol. 1976, 102: 534-536.PubMed Druck NS, Spector GJ, Ciralsky RH, Ogura JH: Malignant Glomus vagale: report of a case and review of the literature. Arch Otolaryngol. 1976, 102: 534-536.PubMed
9.
go back to reference Joynt KE, Moslehi JJ, Baughman KL: Paragangliomas: etiology, presentation, and management. Cardiol Rev. 2009, 17: 159-164. 10.1097/CRD.0b013e3181a6de40.CrossRefPubMed Joynt KE, Moslehi JJ, Baughman KL: Paragangliomas: etiology, presentation, and management. Cardiol Rev. 2009, 17: 159-164. 10.1097/CRD.0b013e3181a6de40.CrossRefPubMed
10.
go back to reference Patel SR, Winchester DJ, Benjamin RS: A 15-year experience with chemotherapy of patients with paraganglioma. Cancer. 1995, 76: 1476-1480. 10.1002/1097-0142(19951015)76:8<1476::AID-CNCR2820760827>3.0.CO;2-9.CrossRefPubMed Patel SR, Winchester DJ, Benjamin RS: A 15-year experience with chemotherapy of patients with paraganglioma. Cancer. 1995, 76: 1476-1480. 10.1002/1097-0142(19951015)76:8<1476::AID-CNCR2820760827>3.0.CO;2-9.CrossRefPubMed
11.
go back to reference Huang H, Abraham J, Hung E, et al: Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer. 2008, 113: 2020-2028. 10.1002/cncr.23812.CrossRefPubMed Huang H, Abraham J, Hung E, et al: Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer. 2008, 113: 2020-2028. 10.1002/cncr.23812.CrossRefPubMed
12.
go back to reference Fitzgerald PA, Goldsby RE, Huberty JP, et al: Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci. 2006, 1073: 465-490. 10.1196/annals.1353.050.CrossRefPubMed Fitzgerald PA, Goldsby RE, Huberty JP, et al: Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci. 2006, 1073: 465-490. 10.1196/annals.1353.050.CrossRefPubMed
13.
go back to reference Bomanji JB, Hyder SW, Gaze MN, et al: Functional imaging as an aid to decision-making in metastatic paraganglioma. Br J Radiol. 2001, 74: 266-269.CrossRefPubMed Bomanji JB, Hyder SW, Gaze MN, et al: Functional imaging as an aid to decision-making in metastatic paraganglioma. Br J Radiol. 2001, 74: 266-269.CrossRefPubMed
14.
go back to reference Sisson JC, Frager MS, Valk TW, et al: Scintigraphic localization of pheochromocytoma. N Engl J Med. 1981, 305: 12-17. 10.1056/NEJM198107023050103.CrossRefPubMed Sisson JC, Frager MS, Valk TW, et al: Scintigraphic localization of pheochromocytoma. N Engl J Med. 1981, 305: 12-17. 10.1056/NEJM198107023050103.CrossRefPubMed
15.
go back to reference Yu L, Fleckman AM, Chadha M, Sacks E, Levetan C, Vikram B: Radiation therapy of metastatic pheochromocytoma: case report and review of the literature. Am J Clin Oncol. 1996, 19: 389-393. 10.1097/00000421-199608000-00015.CrossRefPubMed Yu L, Fleckman AM, Chadha M, Sacks E, Levetan C, Vikram B: Radiation therapy of metastatic pheochromocytoma: case report and review of the literature. Am J Clin Oncol. 1996, 19: 389-393. 10.1097/00000421-199608000-00015.CrossRefPubMed
16.
go back to reference Mertens WC, Grignon DJ, Romano W: Malignant paraganglioma with skeletal metastases and spinal cord compression: response and palliation with chemotherapy. Clin Oncol (R Coll Radiol). 1993, 5: 126-128.CrossRef Mertens WC, Grignon DJ, Romano W: Malignant paraganglioma with skeletal metastases and spinal cord compression: response and palliation with chemotherapy. Clin Oncol (R Coll Radiol). 1993, 5: 126-128.CrossRef
17.
go back to reference Jimenez C, Cote G, Arnold A, Gagel RF: Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes?. J Clin Endocrinol Metab. 2006, 91: 2851-2858. 10.1210/jc.2005-2178.CrossRefPubMed Jimenez C, Cote G, Arnold A, Gagel RF: Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes?. J Clin Endocrinol Metab. 2006, 91: 2851-2858. 10.1210/jc.2005-2178.CrossRefPubMed
18.
go back to reference Sanders KW, Abreo F, Rivera E, Stucker FJ, Nathan CO: A diagnostic and therapeutic approach to paragangliomas of the larynx. Arch Otolaryngol Head Neck Surg. 2001, 127: 565-569.CrossRefPubMed Sanders KW, Abreo F, Rivera E, Stucker FJ, Nathan CO: A diagnostic and therapeutic approach to paragangliomas of the larynx. Arch Otolaryngol Head Neck Surg. 2001, 127: 565-569.CrossRefPubMed
Metadata
Title
Malignant head and neck paragangliomas: Is there an optimal treatment strategy?
Authors
Daniel J Moskovic
Joseph R Smolarz
Douglas Stanley
Camilo Jimenez
Michelle D Williams
Ehab Y Hanna
Michael E Kupferman
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Head & Neck Oncology / Issue 1/2010
Electronic ISSN: 1758-3284
DOI
https://doi.org/10.1186/1758-3284-2-23

Other articles of this Issue 1/2010

Head & Neck Oncology 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine